Jan 11, 2022 / 02:45PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst
Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Teva today at the 40th Annual JPMorgan Conference. From the company, we have Kare Schultz, President and CEO. (Operator Instructions)
And so with that, Kare, Happy New Year. Thanks for joining us, and looking forward to your remarks.
Kare Schultz - Teva Pharmaceutical Industries Limited - President, CEO & Director
Thank you very much, Chris, and welcome to all of you listening in and watching this. I would like to address four important issues that are of high relevance to us in Teva. First, I would like to give you an update on how we plan to solve the litigation challenges we have on the opioid litigation and what the status is. Then I'll give you an idea about how we are going about optimizing our business, focus on the progress we're making on reducing our debt. And then last but not least, I'll explain how we're securing our future sales growth.
But let's
Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot